Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.63 |
| ▸ | IDO1 | P14902 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | MMP8 | P22894 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | MMP1 | P03956 | 1/20 | 0.53 |
| ▸ | MMP3 | P08254 | 1/20 | 0.53 |
| ▸ | MMP9 | P14780 | 1/20 | 0.53 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4961185 | 0.95 | SIGMAR1 (0.62) | POLBSIGMAR1IDO1KMT2AGAA | |
| SCHEMBL12333754 | 0.94 | SIGMAR1 (0.58) | POLBSIGMAR1IDO1L3MBTL1KMT2A | |
| SCHEMBL22102023 | 0.94 | NPSR1 (0.61) | POLBSIGMAR1IDO1KMT2AGAA | |
| SCHEMBL5468072 | 0.94 | NPSR1 (0.61) | POLBSIGMAR1IDO1KMT2AGAA | |
| SCHEMBL12329858 | 0.91 | SIGMAR1 (0.57) | POLBSIGMAR1IDO1L3MBTL1KMT2A | |
| SCHEMBL572740 | 0.90 | IDO1 (0.60) | SIGMAR1IDO1CYP2C9CYP2C19GAA | |
| SCHEMBL24815312 | 0.90 | SIGMAR1 (0.58) | POLBSIGMAR1IDO1L3MBTL1KMT2A | |
| SCHEMBL16808347 | 0.88 | MAPT (0.59) | POLBSIGMAR1IDO1L3MBTL1NPSR1 | |
| SCHEMBL6274138 | 0.88 | NPSR1 (0.56) | POLBSIGMAR1IDO1KMT2AHPGD | |
| SCHEMBL4656567 | 0.87 | S1PR1 (0.60) | POLBSIGMAR1IDO1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5801183-A | HETEROCYCLC ALCOHOLS FOR NERVOUS SYSTEM DISORDERS | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON (US) | 1998-09-01 | — | — | US | claimed |
| US-20230312536-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11634412-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| WO-2018154466-A1 | DIHYDROQUINOLIZINONES AS ANTIVIRALS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-08-30 | — | — | WO | disclosed |
| CN-102859439-B | Positive radiation-sensitive composition, display element interlayer dielectric and forming method thereof | JSR株式会社 | 2017-06-30 | — | — | CN | disclosed |
| US-9598384-B2 | 3-(2-amino-ethyl)-alkylidene)-thiazolidine-2,4-dione and 1-(2-amino-ethyl)-alkylidene-1,3-dihydro-indol-2-one derivatives as selective sphingosine kinase 2 inhibitors | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160159758-A1 | 3-(2-AMINO-ETHYL)-ALKYLIDENE)-THIAZOLIDINE-2,4-DIONE AND 1-(2-AMINO-ETHYL)-ALKYLIDENE-1,3-DIHYDRO-INDOL-2-ONE DERIVATIVES AS SELECTIVE SPHINGOSINE KINASE 2 INHIBITORS | UNIV VIRGINIA COMMONWEALTH (US) | 2016-06-09 | — | — | US | disclosed |
| CN-103119031-B | Substituted amide compounds | ASTELLAS PHARMA INC | 2015-01-14 | — | — | CN | disclosed |
| CN-104220421-A | Sulfonamide derivatives of benzylamine for the treatment of central nervous system disorders | ADAMED SP ZOO | 2014-12-17 | — | — | CN | disclosed |
| EP-2763990-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-08-13 | — | — | EP | disclosed |
| CN-1251586-A | Noval pyrimidine derivatives and process and preparing thereof | YUHAN CORP (KR) | 2000-04-26 | — | — | CN | disclosed |
| US-5801183-A | HETEROCYCLC ALCOHOLS FOR NERVOUS SYSTEM DISORDERS | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON (US) | 1998-09-01 | — | — | US | disclosed |
| EP-0805809-A2 | AZA AND AZA (N-OXY) ANALOGS OF GLYCINE/NMDA RECEPTOR ANTAGONISTS | State of Oregon through Oregon State Board of Higher Education for and on behalf of Oregon Health Sc. Univ. & Univ. of Oregon (US) | 1997-11-12 | — | — | EP | disclosed |
| WO-1996022990-A2 | AZA AND AZA (N-OXY) ANALOGS OF GLYCINE/NMDA RECEPTOR ANTAGONISTS | STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and onbehalf of THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE, OREGON (US) | 1996-08-01 | — | — | WO | disclosed |
| US-5475008-A | Selective non-competitive antagonists of n-methyl-d-aspartate receptors | MERCK SHARP & DOHME LIMITED (GB) | 1995-12-12 | — | — | US | disclosed |
| EP-0459561-B1 | Dioxo-tetrahydroquinoline derivatives | MERCK SHARP & DOHME (GB) | 1995-09-20 | — | — | EP | disclosed |
| EP-0614363-A1 | QUINOLONE DERIVATIVES | MERCK SHARP & DOHME LTD. (GB) | 1994-09-14 | — | — | EP | disclosed |
| US-5268378-A | Oxo group in 2 and 4 position | MERCK SHARP & DOHME, LIMITED (GB) | 1993-12-07 | — | — | US | disclosed |
| WO-1993010783-A2 | QUINOLONE DERIVATIVES AND THEIR USE AS AMPA AND NMDA RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1993-06-10 | — | — | WO | disclosed |
| EP-0459561-A2 | Dioxo-tetrahydroquinoline derivatives | MERCK SHARP & DOHME LTD. (GB) | 1991-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634412-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | PHGDH, G6PD, PGD | POLB 677/4885SIGMAR1 4750/4885IDO1 2084/4885 |
| US-20160159758-A1 | 3-(2-AMINO-ETHYL)-ALKYLIDENE)-THIAZOLIDINE-2,4-DIONE AND 1-(2-AMINO-ETHYL)-ALKYLIDENE-1,3-DIHYDRO-INDOL-2-ONE DERIVATIVES AS SELECTIVE SPHINGOSINE KINASE 2 INHIBITORS | SPHK2, SPHK1, S1PR2 | POLB 3760/4885SIGMAR1 2249/4885IDO1 533/4885 |
| US-20230312536-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | PHGDH, G6PD, PGD | POLB 677/4885SIGMAR1 4750/4885IDO1 2084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.